Welcome!

News Feed Item

The Pharmaceutical Market: UK

NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: UK

http://www.reportlinker.com/p0203096/The-Pharmaceutical-Market-UK.html#u...

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

Snapshot: Strategic Espicom Analysis 2

Snapshot: Key Data Projections3

MACROENVIRONMENT 4

POLITICAL 4

ECONOMIC5

Projections 5

LEGAL6

EU Patent Protection & Intellectual Property Rights 6

Proposal for Unitary Patent 6

EU Supplementary Protection Certificates6

EU Data Exclusivity6

DEMOGRAPHIC 7

Projections 7

Demographic Indicators8

Births 8

Deaths 8

Infant Deaths 8

Life Expectancy at Birth 8

EPIDEMIOLOGY 9

DISEASE BURDEN 9

Leading Causes of Mortality9

DISEASE PREVALENCE10

Communicable Diseases 10

HIV/AIDS 10

Non-Communicable Diseases 11

Cancer 11

Diabetes 11

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12

EU DIRECTIVE12

Cross-Border Healthcare Directive 12

ORGANISATION 12

Performance 12

Structure 13

Department of Health 14

Strategic Health Authorities 14

Primary Care Trusts 14

Acute Trusts 14

NHS Foundation Trusts 14

NHS Care Trusts 15

Ambulance Trusts 15

Care Quality Commission 15

EXPENDITURE 17

Projections 17

NHS Budget 18

Private Healthcare 18

INFRASTRUCTURE 19

Hospital Infrastructure19

Private Hospital Operators19

BMI Healthcare 19

HCA International 19

Netcare 19

NHS Trusts 20

Nuffield Health 20

Partnership Health Group (PHG) 20

Ramsay Healthcare20

Spire Healthcare 20

Ambulatory Infrastructure21

SERVICES 21

Hospital Inpatient Services 21

Outpatient Services22

WORKFORCE 22

Projections 22

Physicians 23

Nurses 23

Dentists 24

Pharmacists 24

REGULATORY AFFAIRS 25

EU REGULATORY AUTHORITY 25

NATIONAL AUTHORITIES 25

MARKETING REGISTRATION 26

EU Marketing Registration26

Centralised Procedure 26

National Procedures 27

IMPORT REGULATIONS 27

Parallel Trade 27

PROMOTION 28

Advertising 28

PRICING & REIMBURSEMENT 29

EU NETWORKING MEETING 29

NM CAPR29

PRICING 29

PPRS Reforms 29

Patient Access Schemes 30

Prescription Charges 31

REIMBURSEMENT 31

DISTRIBUTION CHANNELS 34

EU DIRECTIVE 34

Falsified Medicines Directive34

DRUG WHOLESALING 34

Association of Wholesalers 34

BAPW34

Leading Wholesalers 35

AAH Pharmaceuticals 35

Alliance Healthcare35

DRUG RETAILING 36

Association of Independent Pharmacies 36

Numark36

Association of Community Pharmacies36

NPA 36

Leading Pharmacy Chains 37

Alliance Boots 37

Lloydspharmacy 37

Superdrug 37

MARKET ANALYSIS 38

SIZE 38

Projections 38

Historical Figures 40

Current Structure 41

PRODUCT DEVELOPMENT 49

EU Programmes49

Horizon 2020 49

IMI 49

National Research & Development 49

MANUFACTURING 52

TRADE53

Exports 53

Imports 56

Balance of Trade 60

COMPETITION 61

TRADE ASSOCIATIONS 61

ABPI 61

COMPANY INTELLIGENCE 62

AstraZeneca62

Eisai62

Eli Lilly 62

GlaxoSmithKline 62

MSD63

Novartis 63

Pfizer 64

ProStrakan64

Shire Pharmaceuticals 65

ViiV Healthcare 65

Competitive Strategies65

GLOBAL COMPANY INTELLIGENCE 66

AstraZeneca66

Company Overview 66

Financial Performance66

Product Portfolio 67

R&D Strategy 69

Manufacturing Capabilities 71

Outlook 71

GlaxoSmithKline 72

Company Overview 72

Financial Performance72

Product Portfolio 73

R&D Strategy 75

Manufacturing Capabilities 76

Outlook 76

Shire 77

Company Overview 77

Financial Performance78

Product Portfolio 79

R&D Strategy 80

Manufacturing Capabilities 81

OTC PHARMACEUTICALS 82

REGULATION 82

Marketing Registration 82

Labelling 82

MARKET SIZE 83

COMPETITION 84

Trade Association84

PAGB 84

GENERIC PHARMACEUTICALS 85

REGULATION 85

EU Marketing Registration85

Pricing & Reimbursement 85

Generic Substitution Plans are Scrapped 85

Unbranded Generic Pricing 85

2005 Generics Reimbursement Scheme 86

MARKET SIZE 87

COMPETITION 90

Trade Association90

BGMA90

Company Intelligence 90

Actavis 90

Bristol Laboratories90

Dr Reddy's 91

Kent Pharmaceuticals 91

Pfizer 91

Rosemont Pharmaceuticals 91

Teva Pharmaceuticals 91

Winthrop Pharmaceuticals 92

Wockhardt 92

BIOLOGICS & BIOSIMILARS 93

REGULATION 93

EU Approval Process 93

EU Regulation of Biosimilars 93

EMA Guideline Documents94

Draft Biosimilar Concept Paper94

Biosimilar mAb Guideline 94

Biosimilars Approved in the EU 95

National Regulation 95

NICE Approves First Biosimilar for NHS Use95

PRODUCT DEVELOPMENT 96

Cancer Research 96

Stem Cell Research 96

COMPETITION 97

Trade Association97

BIA 97

Company Intelligence 97

Angel Biotechnology97

Argenta 97

Ark Therapeutics 98

Astex Therapeutics98

BigDNA98

BioFocus 98

Biogen Idec 98

BTG 99

Cellartis99

Convergence Pharmaceuticals 99

FMC BioPolymer 99

ImmuPharma 99

Intercell 99

Lonza 100

NovaBiotics100

Oxford BioMedica100

PolyTherics 100

Silence Therapeutics 101

UCB 101

Competitive Strategies 101

CONCLUSIONS: OPPORTUNITIES & CHALLENGES 103

Strategic Espicom Analysis 103

MACROENVIRONMENT 103

EPIDEMIOLOGY 103

HEALTHCARE103

REGULATORY AFFAIRS104

PRICING & REIMBURSEMENT 104

DISTRIBUTION CHANNELS 105

MARKET 105

COMPETITION 106

OTC PHARMACEUTICALS 106

GENERIC PHARMACEUTICALS106

BIOLOGICS & BIOSIMILARS 106

Radar Analysis 108

SWOT Analysis 108

DIRECTORY 109

GOVERNMENT ORGANISATIONS 109

PHARMACEUTICAL COMPANIES 109

Biologic Companies 109

Generic Companies 109

PHARMACEUTICAL DISTRIBUTORS110

PHARMACY CHAINS 110

TRADE ORGANISATIONS110

List of Tables

Espicom Analysis of the Pharmaceutical Market, 2012 2

Key Data Projections, 2012-2017 3

Political Landscape, 2012 4

Regional Ranking of Projected Economies, 2017 5

Projected Economy, 2012-2017 5

Regional Ranking of Projected Demographics, 2017 7

Projected Demographics, 2012-2017 7

Demographic Indicators, 2002-2009 8

Causes of Death by Country, 2010 9

HIV and AIDS Cases, up to 2010 10

Regional Ranking of Projected Health Expenditure, 2017 17

Projected Health Expenditure, 2012-201717

Inpatient Procedures and Interventions by Type, 2010/11 21

Regional Ranking of Projected Physicians, 2017 22

Projected Physicians, 2012-2017 22

Consultants by Specialty in England, 2008-2010 23

NHS Nurses by Country, 2007-2009 23

Patient Access Schemes in Published Guidance, 2007-2010 30

NICE Appraisals in Development, January 2012 31

Members of BAPW, 2011 34

Celesio's Revenue from Wholesale Activities, 2007-2009 (Euro Millions) 35

Alliance Healthcare's Financial Highlights, 2008-2010 (£ Millions) 35

Regional Ranking of Projected Pharmaceutical Markets, 2017 38

Projected Pharmaceutical Market at Retail Prices, 2012-2017 38

Historical Pharmaceutical Market at Retail Prices, 1995-2011 40

Written Prescriptions, 2006-2010 (Millions) 41

Prescriptions by Value, 2006-2010 (£ Millions) 41

Prescriptions & Cost by Therapeutic Area in the UK, 2010 42

Prescriptions & Cost by Therapeutic Area in England, 2010 43

Top 20 Prescribed Drugs in England by Value, 2010 44

Top 20 Prescribed Drugs in England by Volume, 2010 45

Cost of Pharmaceuticals Issued by Hospital Pharmacies in England, 2003-2010 (£ Millions) 45

Prescriptions & Cost by Therapeutic Area in Wales, 2010 46

Prescriptions & Cost by Therapeutic Area in Scotland, 2010 47

Prescriptions & Cost by Therapeutic Area in Northern Ireland, 201048

Pharmaceutical R&D Expenditure, 1972-2007 (£ Millions) 50

Pharmaceutical Production, 1995-2010 (Euros 000s) 52

Pharmaceutical Exports by Category, 1995-2010 (US$000s) 53

Pharmaceutical Exports by Country/Region, 2010 (US$000s) 55

Pharmaceutical Imports by Category, 1995-2010 (US$000s) 56

Imports of Raw Materials by Country/Region, 2010 (US$000s) 58

Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s) 58

Imports of Medicaments by Country/Region, 2010 (US$000s) 59

Balance of Pharmaceutical Trade, 1995-2010 (US$000s) 60

Full Members of the ABPI, 2011 61

AstraZeneca's Principal Operating Results, 2006-2010 (US$ Million) 66

AstraZeneca's Sales by Geographic Area, 2006-2010 (US$ Million) 67

AstraZeneca's Sales by Leading Products, 2006-2010 (US$ Million)68

AstraZeneca's Recent Product Approvals, 2010-2011 69

AstraZeneca's Major Manufacturing Facilities by Location, 2011 71

GSK's Principal Operating Results, 2006-2010 (£ Million) 73

GSK's Sales by Geographic Area, 2007-2010 (£ Million) 73

GSK's Sales by Leading Products, 2006-2010 (£ Million) 74

GSK's Recent Product Approvals, 2010-2011 75 Shire's Principal Operating Results, 2006-2010 (US$ Million) 78

Shire's Revenue by Business Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Geographic Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Leading Products, 2006-2010 (US$ Million) 79

Shire's Recent Product Approvals, 2010-2011 80

Shire's Major Manufacturing Facilities by Location, 2011 81

OTC Sales at Retail Prices, 2007-2010 (£ Millions) 83

Full Members of PAGB, 2011 84

Prescriptions Written and Dispensed Generically in England by Value, 1996-2010 (£ Millions) 87

Prescriptions Written and Dispensed Generically in England by Volume, 1996-2010 (Millions) 88

Generic Prescribing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 88

Generic Dispensing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 89

Members of BGMA, 2011 90

Biosimilars Approved in the EU 95

Espicom Analysis of the Pharmaceutical Market, 2012 107

SWOT Analysis of the Pharmaceutical Market, 2012 108

List of Charts

Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices, 2017 39

Regional Comparison of Projected Pharmaceutical Market Share, 2017 39

Historical Pharmaceutical Market at Retail Prices, 1995-201140

Pharmaceutical Exports, 1995-2010 (US$ Billions) 54

Pharmaceutical Exports by Country/Region, 2010 (%) 54

Pharmaceutical Imports, 1995-2010 (US$ Billions) 56

Imports of Pharmaceuticals by Country/Region, 2010 (%) 57

Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)60

Radar Graph of the Pharmaceutical Market, 2012 108

To order this report:

Pharmaceutical Industry: The Pharmaceutical Market: UK

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When applications are hosted on servers, they produce immense quantities of logging data. Quality engineers should verify that apps are producing log data that is existent, correct, consumable, and complete. Otherwise, apps in production are not easily monitored, have issues that are difficult to detect, and cannot be corrected quickly. Tom Chavez presents the four steps that quality engineers should include in every test plan for apps that produce log output or other machine data. Learn the ste...
Digital Transformation is well underway with many applications already on the cloud utilizing agile and devops methodologies. Unfortunately, application security has been an afterthought and data breaches have become a daily occurrence. Security is not one individual or one's team responsibility. Raphael Reich will introduce you to DevSecOps concepts and outline how to seamlessly interweave security principles across your software development lifecycle and application lifecycle management. With ...
The vast majority of businesses now use cloud services, yet many still struggle with realizing the full potential of their IT investments. In particular, small and medium-sized businesses (SMBs) lack the internal IT staff and expertise to fully move to and manage workloads in public cloud environments. Speaker Todd Schwartz will help session attendees better navigate the complex cloud market and maximize their technical investments. The SkyKick co-founder and co-CEO will share the biggest challe...
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
Machine learning provides predictive models which a business can apply in countless ways to better understand its customers and operations. Since machine learning was first developed with flat, tabular data in mind, it is still not widely understood: when does it make sense to use graph databases and machine learning in combination? This talk tackles the question from two ends: classifying predictive analytics methods and assessing graph database attributes. It also examines the ongoing lifecycl...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Behera Rasananda is a technologist, a leader, a key note speaker has more than 20 years experience in across Government, Financial, Heath Care and Insurance Verticals. Mr. Behera has vast experience in Enterprise Cloud and Big Data solutions and Enterprise Architecture. Currently he works closely for Government Solutions on Enterprise Cloud for Federal Government Agency. Scientist Behera managed and partner with clients to make complete end to end solution and Migration to cloud both private sec...